MXPA02009744A - Uso de fulvestrant en el tratamiento de cancer resistente de mama. - Google Patents

Uso de fulvestrant en el tratamiento de cancer resistente de mama.

Info

Publication number
MXPA02009744A
MXPA02009744A MXPA02009744A MXPA02009744A MXPA02009744A MX PA02009744 A MXPA02009744 A MX PA02009744A MX PA02009744 A MXPA02009744 A MX PA02009744A MX PA02009744 A MXPA02009744 A MX PA02009744A MX PA02009744 A MXPA02009744 A MX PA02009744A
Authority
MX
Mexico
Prior art keywords
fulvestrant
treatment
breast cancer
resistant breast
resistant
Prior art date
Application number
MXPA02009744A
Other languages
English (en)
Inventor
Beat Thurlimann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02009744(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA02009744A publication Critical patent/MXPA02009744A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere al uso de fulvestrant en tratamiento de cancer de mama en pacientes que han sido tratados previamente con un Modular del Receptor del Estrogeno Selectivo (SERM) y un inhibidor de aromatasa.
MXPA02009744A 2000-04-05 2001-04-02 Uso de fulvestrant en el tratamiento de cancer resistente de mama. MXPA02009744A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy
PCT/GB2001/001500 WO2001074366A1 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer

Publications (1)

Publication Number Publication Date
MXPA02009744A true MXPA02009744A (es) 2004-02-26

Family

ID=9889101

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009744A MXPA02009744A (es) 2000-04-05 2001-04-02 Uso de fulvestrant en el tratamiento de cancer resistente de mama.

Country Status (29)

Country Link
US (2) US20030158166A1 (es)
EP (2) EP1272195B1 (es)
JP (1) JP2003528919A (es)
KR (1) KR100757764B1 (es)
CN (1) CN1431905A (es)
AT (1) ATE306270T1 (es)
AU (2) AU2001244372B2 (es)
BR (1) BR0109789A (es)
CA (1) CA2403608A1 (es)
CH (1) CH1272195H1 (es)
CZ (1) CZ303096B6 (es)
DE (1) DE60113975T2 (es)
DK (1) DK1272195T3 (es)
EE (1) EE05026B1 (es)
ES (1) ES2248300T3 (es)
GB (1) GB0008172D0 (es)
HK (1) HK1051498A1 (es)
HU (1) HU230064B1 (es)
IL (2) IL151932A0 (es)
IS (1) IS2869B (es)
MX (1) MXPA02009744A (es)
NO (1) NO329949B1 (es)
NZ (1) NZ539603A (es)
PL (1) PL201175B1 (es)
RU (1) RU2265438C2 (es)
SK (1) SK287779B6 (es)
UA (1) UA80388C2 (es)
WO (1) WO2001074366A1 (es)
ZA (1) ZA200207538B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
RU2004102393A (ru) * 2001-07-07 2005-03-27 Астразенека Аб (Se) Фармацевтическая композиция для внутримышечного введения фульвестранта
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
WO2007062093A2 (en) * 2005-11-22 2007-05-31 Incyte Corporation Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
SG194735A1 (en) * 2011-05-09 2013-12-30 Univ Virginia Patent Found Compositions and methods for treating cancer
ES2708302T3 (es) 2011-05-20 2019-04-09 Capital Business Y Gestion De Finanzas S L Composición farmacéutica
EP3092027A4 (en) * 2014-01-10 2017-09-06 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
JP2020533283A (ja) 2017-09-11 2020-11-19 アトッサ セラピューティクス，インク． エンドキシフェンを製造および使用する方法
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ
CA3210276A1 (en) * 2020-02-29 2021-09-02 Frances E. Carr Use of thyromimetics for the treatment of cancer

Also Published As

Publication number Publication date
GB0008172D0 (en) 2000-05-24
RU2265438C2 (ru) 2005-12-10
IL151932A (en) 2007-07-04
WO2001074366A1 (en) 2001-10-11
NZ539603A (en) 2008-02-29
AU2001244372B2 (en) 2006-02-16
CA2403608A1 (en) 2001-10-11
SK14292002A3 (sk) 2003-08-05
DE60113975D1 (de) 2006-02-23
JP2003528919A (ja) 2003-09-30
NO20024735D0 (no) 2002-10-02
DK1272195T3 (da) 2006-01-16
SK287779B6 (sk) 2011-09-05
EE200200574A (et) 2004-04-15
EP1586323A1 (en) 2005-10-19
HU230064B1 (hu) 2015-06-29
HUP0300339A3 (en) 2009-01-28
CN1431905A (zh) 2003-07-23
NO20024735L (no) 2002-11-27
CH1272195H1 (es) 2019-10-15
ES2248300T3 (es) 2006-03-16
CZ303096B6 (cs) 2012-04-04
EP1272195A1 (en) 2003-01-08
PL201175B1 (pl) 2009-03-31
US20110183949A1 (en) 2011-07-28
DE60113975T2 (de) 2006-06-22
BR0109789A (pt) 2003-01-21
KR20030007501A (ko) 2003-01-23
CZ20023309A3 (cs) 2003-02-12
EP1272195B1 (en) 2005-10-12
IL151932A0 (en) 2003-04-10
KR100757764B1 (ko) 2007-09-12
US20030158166A1 (en) 2003-08-21
PL357936A1 (en) 2004-08-09
HUP0300339A2 (hu) 2003-06-28
HK1051498A1 (en) 2003-08-08
ATE306270T1 (de) 2005-10-15
IS6576A (is) 2002-10-01
NO329949B1 (no) 2011-01-31
IS2869B (is) 2014-03-15
ZA200207538B (en) 2003-12-19
AU4437201A (en) 2001-10-15
EE05026B1 (et) 2008-06-16
UA80388C2 (en) 2007-09-25

Similar Documents

Publication Publication Date Title
MX9700534A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
HUS1500001I1 (hu) ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére
EP1355563A4 (en) METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
SG148864A1 (en) Methods of treating cancer and related methods
TW200612918A (en) Lonidamine analogs
IL143870A0 (en) Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
MXPA05012421A (es) Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
PL365244A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
MXPA02009744A (es) Uso de fulvestrant en el tratamiento de cancer resistente de mama.
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
MY138883A (en) Use of asiatic acid for treatment of cencer
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
GB0020504D0 (en) Therapeutic method
HK1043058A1 (zh) 異環磷酰胺芥子類似物及其用途
HUP0301123A3 (en) Use of exemestane for treatment of hormone-dependent breast cancer
TW200503731A (en) Method of treatment
AU2003250912A8 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
MXPA03002494A (es) Metodo para reducir toxicidad de quimio terapias combinadas.
RS37804A (en) Use of n,n-diethyl-2-/-4-(phenylmethyl)- phenoxy/ethanamine monohydrochloride (dppe)in cancer therapy
SI1272195T1 (sl) Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk
UA28113C2 (uk) Спосіб експрес-тестування ефективності реабілітації здоров'я людини
GB0115943D0 (en) Treatment and diagosis of cancer

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration